Please assess the completion status of the following clinical trial:

Trial Title: Phase 1b Influenza Vaccine Study in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must have a BMI \>18.5 and ≤ 28.5 kg/m2.~* Subject must have no clinically significant abnormal findings, as judged by the Investigator, on the physical examination, ECG, medical history or clinical laboratory results during screening.~* Subject must be a non-user of tobacco products, or smoke ≤ 10 cigarettes per day (minimum 6 months prior to first dose).~* Subject must have a negative urine screen for drugs of abuse and a negative alcohol breath test at screening and check-in.~* Subject must refrain from consuming alcohol for 72 hours prior to each dose.~* Subject must be able to communicate well with the Investigator, to understand and comply with the requirements of the study, and be judged suitable for the study in the opinion of the Investigator.~* Subject must give voluntary written informed consent to participate in this trial.~Exclusion Criteria:~* Subject must not have previous influenza vaccination within the 12 months prior to test drug vaccination.~* Subject must not have had an influenza like illness within the 3 months prior to test drug vaccination.~* Subject must not have a history or presence of significant neurological, cardiovascular, pulmonary (including asthma), hepatic, metabolic, rheumatic, autoimmune, haematological or renal disorder.~* Subject must not have an oral temperature \>38°C on day of vaccination (otherwise subject maybe be re-assigned to a subsequent cohort).~* Subject must not suffer from an inherited or acquired immunodeficiency.~* Subject must not suffer from a disease or be undergoing treatment that can affect immune response such as systemic or high dose inhaled corticosteroids (\>800µg/day beclometasone or equivalent), radiation treatment, cytotoxic drugs or non-steroidal anti-inflammatory drugs.~* Subject must not have a serologically positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).~* Subject must not have a history of severe allergic reactions and/or anaphylaxis.~* Subject must not have any arm rash or tattoos which could confound the interpretation of any injection site reactions.~* Subject must not have participated in a previous clinical trial within 90 days prior to the first vaccination.~* Subject must not have donated blood or plasma more within 90 days prior to the first vaccination.~* Subject must not have donated bone marrow within 6 months prior to the first dose.~* Subject must not have received administration of immunoglobulins and/or any blood products within 90 days prior to the first vaccination, or any planned administration during the study period.~* Subject must not use any prescription medication within 14 days prior to the first vaccination.~* Subject must not use over-the-counter (OTC) medication 7 days prior to the first vaccination. Exceptions are described below under the heading 9.4.1.~* Subject must not have received any vaccine within the 30 days prior to the first dose, and must agree not to receive any other vaccine (other than any vaccine indicated for standard of care, for example, tetanus vaccine) for the duration of this study i.e 21 days post initial FLU-v vaccination.~* Subject must not have a history of alcohol or drug abuse within 2 years prior to the first dose.~* Subject must not have any condition which, in the judgement of the Investigator, precludes inclusion into the study.~* Subjects must not donate sperm up to 90 days postdose, and those whose partner is of child-bearing potential will be advised to remain sexually inactive or use a dual method of birth control (e.g. condom together with spermicidal agent, IUD or hormonal contraception) for at least 90 days postdose.~* Subject must not be a direct employee of the study site, monitoring CRO or Sponsor.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Group 2 (Type: EXPERIMENTAL): FLU-v Low Dose with adjuvant. FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection.~10 subjects.
- Group 3 (Type: EXPERIMENTAL): FLU-v High Dose with water for injection. FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection.~10 subjects.
- Group 4 (Type: EXPERIMENTAL): High Dose FLU-v with adjuvant FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection. 10 subjects
- Group 1 (Type: EXPERIMENTAL): FLU-v Low Dose with water for injection FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection 10 subjects
- Control Group (Type: PLACEBO_COMPARATOR): Placebo with adjuvant (4 subjects) or Placebo without adjuvant (4 subjects)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete